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Abstract
Background: During adulthood, personality characteristics may contribute to the individual capacity to compensate
the impact of developing cerebral Alzheimer’s disease (AD) pathology on cognitive impairment in later life. In this
study we aimed to investigate whether and how premorbid personality traits interact with cerebrospinal fluid (CSF)
markers of AD pathology to predict cognitive performance in subjects with mild cognitive impairment or mild AD
dementia and in participants with normal cognition.
Methods: One hundred and ten subjects, of whom 66 were patients with mild cognitive impairment or mild AD
dementia and 44 were healthy controls, had a comprehensive medical and neuropsychological examination as well as
lumbar puncture to measure CSF biomarkers of AD pathology (amyloid beta1–42, phosphorylated tau and total-tau).
Participants’ proxies completed the Revised NEO Personality Inventory, Form R to retrospectively assess subjects’
premorbid personality.
Results: In hierarchical multivariate regression analyses, including age, gender, education, APOEε4 status and cognitive
level, premorbid neuroticism, conscientiousness and agreeableness modulated the effect of CSF biomarkers on
cognitive performance. Low premorbid openness independently predicted lower levels of cognitive functioning after
controlling for biomarker concentrations.
Conclusion: Our findings suggest that specific premorbid personality traits are associated with cerebral AD pathology
and modulate its impact on cognitive performance. Considering personality characteristics may help to appraise a
person’s cognitive reserve and the risk of cognitive decline in later life.
Keywords: Premorbid personality, Cerebrospinal fluid biomarkers, Alzheimer’s disease, Mild cognitive impairment,
Cognition
Background
With the rising number of older people suffering from
Alzheimer’s disease (AD), it is of high clinical importance
to investigate its early clinical stages (i.e. mild cognitive
impairment (MCI)) as well as to identify lifestyle-related
factors that influence the relationship between cerebral
pathology and cognitive impairment. Patients with MCI
are characterized by a noticeable decline in cognitive abil-
ities, which is relatively greater than normal age-related
change observed in the healthy population, and have an
increased risk of developing AD dementia during the fol-
lowing year. The underlying pathologies are heteroge-
neous and only some patients have cerebral AD pathology
as the main cause of cognitive impairment. Cerebrospinal
fluid (CSF) AD biomarkers reflect the cerebral accumula-
tion of specific pathology; that is, the extracellular plaques
containing amyloid beta (Aβ) [1, 2] and the neurofibrillary
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tangles, associated with tau protein abnormalities and
neurodegeneration [3, 4]. Compared with controls, mildly
demented AD patients show decreased Aβ1–42 levels and
elevated tau protein levels in CSF [5, 6]. Studies show that
these neuropathological changes precede the symptoms of
clinical dementia by years [7, 8], and thus tau, phosphory-
lated tau (ptau) and Aβ1–42 in CSF can be considered a
valuable detector of AD at a very early stage.
The risk of dementia has been reported to be associated
with specific premorbid personality characteristics [9]. Per-
sonality is described as a more or less stable organization of
character, temperament and intelligence of a person that
determines adaptation to the environment [10]. Personality
traits represent individual tendencies to think, feel and be-
have in certain ways that affect our interactions with the ex-
ternal world [11]. Because personality influences lifestyle
patterns such as health habits, cognitive activity and social
relationships [12, 13], and these factors in turn are related
to the risk of developing dementia in later life [14–16], per-
sonality characteristics may represent important determi-
nants of dementia risk.
In Alzheimer’s type of dementia, the age of onset and the
magnitude of cognitive impairment may depend on the in-
dividual’s capacity to compensate cerebral pathology and
dysfunction, referred to as cognitive reserve [16]. Beginning
as early as in young adulthood, personality characteristics
may contribute to cognitive reserve by their influences on
lifestyle and health-related behaviour. A resilient personality
profile may be associated with lower risk of clinical demen-
tia in persons with AD neuropathology. Wilson et al. [17]
have shown an association between higher levels of con-
scientiousness and reduction in MCI and AD incidence
and reduced cognitive decline. Likewise, two comprehen-
sive meta-analyses showed consistent evidence for associa-
tions between higher premorbid neuroticism and increased
risk of dementia, while higher levels of conscientiousness
were demonstrated to act as protective factors for dementia
incidence [18, 19]. These studies have not included evalu-
ation of cerebral AD pathology, however. One prospective
autopsy study showed that in subjects confirmed to have
AD neuropathology, greater scores on conscientiousness
and lower scores on neuroticism were associated with re-
duced risk or delay to develop clinical dementia [20].
Information regarding personality traits is accessible
through questionnaires completed by patients’ rela-
tives, and does not involve any invasive techniques.
Evaluating subjects’ personality may add significant
information on the risk of AD dementia and favour
the prevention of cognitive decline. The possible in-
fluence of premorbid personality characteristics on
the relationship between cognitive functioning and
AD pathology, as measured by CSF biomarkers at
early clinical disease stages, has not yet been ques-
tioned. With this study we aim:
(1) to explore the relationship between premorbid
personality traits and cognitive functioning in
cognitively impaired patients and healthy older
subjects; and
(2) to investigate whether specific personality traits
modulate the relationship between cognitive
performance and cerebral AD pathology as
measured by CSF biomarkers in subjects with
MCI or mild dementia and in subjects with
normal cognition.
Method
Subjects
One hundred and ten community-dwelling participants
were included in this study, of whom 44 were cognitively
healthy volunteers and 66 had cognitive impairment, ei-
ther MCI (n = 57) or mild dementia AD (n = 9) (see Table 1
for a detailed sample description). The participants with
cognitive impairment were recruited among patients at-
tending the Memory Clinics of the Department of Psych-
iatry and the Department of Clinical Neurosciences at
Lausanne University Hospital, and met the diagnostic cri-
teria for MCI [21] or mild dementia [22]. The patients
had no major psychiatric or neurological disorders, nor
substance abuse or severe or unstable physical illness that
explained cognitive impairment. Control subjects had no
history, symptoms or signs of relevant psychiatric or
neurologic disease and no cognitive impairment. Healthy
subjects were recruited in the community through journal
announcements and word of mouth. All participants had
a comprehensive medical, psychiatric, neuropsychological
and psychosocial evaluation, as well as brain MRI or CT
scans and venous and lumbar puncture. The MRI and CT
scans were used in order to exclude patients with cerebral
pathologies possibly interfering with cognitive perform-
ance, including relevant vascular damage.
Procedure
The study was approved by the Ethics Committee of the
canton of Vaud, Switzerland. The aims of the research
project were clearly explained to all participants and the
informed written consent to participate in the study was
administered and signed by all.
Diagnosis of MCI or mild AD dementia was based on
clinical and neuropsychological evaluation as well as on
psychosocial and functional assessment (see later) and was
made at a consensus conference of psychiatrists, neuropsy-
chologists and/or neurologists prior to inclusion into the
study. MCI was diagnosed according to widely used con-
sensus recommendations [21]. Participants in this group
had memory impairment (<–1.5 standard deviation (SD)
below the means adjusted for gender, age and education in
the verbal memory task of the Buschke Double Memory
Test [23]) and/or impairment in another cognitive domain,
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and a Clinical Dementia Rating (CDR) [24] score of 0.5.
The diagnosis of probable AD dementia was based on the
clinical diagnostic criteria for probable dementia due to AD
according to recommendations from the National Institute
on Aging and Alzheimer’s Association [25] and DSM-IV
criteria for dementia of Alzheimer type [22]. Participants in
this group had a CDR score of 1. Participants without cog-
nitive impairment had no history or evidence of cognitive
decline, and their CDR score was 0.
The CDR is a semi-structured, clinician-rated interview
with the patient and an appropriate informant, widely used
to assess the progression of dementia. It is based on the rat-
ings of the patient’s cognitive and functional impairment in
six domains usually affected in AD: memory, orientation,
judgement and problem-solving, community affairs, home
and hobbies, and personal care [24]. Scores in each of area
range from 0 to 3, representing “none” to “severe” impair-
ment. CDR has a very high inter-rater reliability [26] and
thus appears to be a reliable and valid measurement for
assessing cognitive performance stages in dementia.
CSF biomarkers and APOE genotyping
Venous and lumbar punctures were performed between
8:30 and 9:30 am after overnight fasting at the recruiting
memory centres. CSF was collected by lumbar puncture
using a standardized technique with a 22 G “atraumatical”
Table 1 Demographics and descriptive statistics
Control Cognitive impairment Statistical
test
P
(n = 44) (n = 66)
Gender Males 14 (31.8%) 30 (45.5%) Chi-square 0.155
Females 30 (68.2%) 36 (54.5%)
Age Mean 66 74 t <0.001
SD 6.57 6.54
Education level ≤9 years 3 (6.8%) 11 (16.7%) Chi-square 0.113
10–12 years 22 (50.0%) 34 (51.5%)
>12 years 19 (43.2%) 21 (31.8%)
CDR SoB Mean 0.23 1.96 t <0.001
SD 0.1 2.16
HAD Depression score Mean 3.79 4.18 t 0.55
SD 3.56 3.06
HAD Anxiety score Mean 6.79 6.45 t 0.65
SD 4.24 3.2
QPC score Mean 1.56 2.54 t <0.01
SD 1.5 1.89
IQCODE score Mean 3.067 3.467 t <0.001
SD 0.42 0.54
APOEε4 carriers No 36 (81.8%) 36 (54.5%) Chi-square <0.01
Yes 8 (18.2%) 29 (43.9%)
Aβ1–42 pg/ml Median 1053 668.75 U <0.001
IQR 289.6 357.8
tau pg/ml Median 209.3 394.35 U <0.001
IQR 115.4 361.3
ptau-181 pg/ml Median 46.5 62.3 U <0.001
IQR 25.2 44.5
tau/Aβ1–42 pg/ml Median 0.219 0.554 U <0.001
IQR 0.115 0.765
ptau-181/Aβ1–42 pg/ml Median 0.047 0.101 U <0.001
IQR 0.02 0.097
CDR SoB Clinical Dementia Rating Sum of Boxes score, HAD Hospital Anxiety and Depression Scale, APOEε4 epsilon 4 allele of Apolipoprotein E, QPC cognitive
complaints questionnaire, IQCODE Informant Questionnaire on Cognitive Decline in the Elderly, Aβ amyloid beta, ptau phosphorylated tau, SD standard deviation,
IQR interquartile range, U, Mann–Whitney U statistic
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spinal needle while the patient was sitting or lying [27].
Samples of 10–12 ml of CSF was obtained for analysis
using polypropylene tubes. Routine CSF cell counts and
protein quantification were performed. The remaining CSF
was centrifuged, frozen in aliquots and stored at –80 °C
until assayed. We measured Aβ1–42, tau and ptau-181 con-
centrations with ELISA kits, using commercially available
assays (Innogenetics/Fujirebio, Gent, Belgium). Carrying
the APOEε4 allele may influence the relationships between
personality, AD pathology, age and clinical manifestations
[28] at very early disease stages [29, 30]. Accordingly, the
APOE genotype was determined (using the LightCycler;
Roche Diagnostics, Basel, Switzerland) and considered in
all main analytical steps. Analyses were performed by oper-
ators who were blind to all clinical information.
Neuropsychological and functional assessment
Neuropsychological tests were used to assess cognitive per-
formance in the domains of memory (spontaneous and
cued-recall 48-items task [31]), executive function—a ver-
bal fluency task (categorical and literal fluency in 2 min), a
flexibility task (the Trail Making Test A and B [32]) and an
inhibition task (the Stroop test [33])—and visuospatial
functions (CERAD copy image test). The MMSE [34] was
used to assess participants’ cognitive level. Depression and
anxiety were assessed using the Hospital Anxiety and
Depression (HAD) scale [35]. A cognitive complaints
questionnaire (Questionnaire de Plainte Cognitive (QPC)
[36, 37]) was employed to evaluate participants’ memory
failures and cognitive complaints.
Psychosocial and functional assessment included the
ADL [38] and instrumental ADL [39], the NPIQ [40] and
the IQCODE [41] questionnaires, completed by family
members of the participants. All tests and scales are vali-
dated and widely used in the field.
Personality assessment
Patients’ proxies were asked to complete the Revised
NEO Personality Inventory, Form R (NEO-PI-R [42]),
which is based on the Five-Factor Model (FFM) [43].
This dimensional personality model, derived from factor
analyses performed on a large number of self-reports
and peer reports on personality-relevant adjectives and
questionnaire items [43], revealed five dimensions de-
scribing personality: neuroticism, extraversion, openness
to experience, agreeableness and conscientiousness. Each
of these dimensions is composed of six subcomponents,
or facets (see Table 3 in Appendix for description of the
domain and facet scales). It was suggested that normal
and pathological personality may be differentiated by the
extremeness of scores on the dimensions of the FFM
[43]. The NEO-PI-R is a questionnaire composed of 240
items and used for peer ratings which has resulted from
comprehensive research on personality change and
stability, and has well-established reliability and validity
data in older populations [44], and was validated with a
French-speaking sample [45]. For this study we used the
informants’ ratings, because subjects with cognitive im-
pairment may provide less reliable information about
their personality due to memory difficulties and poor
insight and judgement [46]. Premorbid personality was
assessed with the NEO-PI-R, Form R where the subjects’
proxies were asked to describe the participants’ person-
ality as it was remembered to be 5 years prior to the be-
ginning of the first symptoms.
Statistical analyses
Data were analysed using SPSS version 20 and R [47]. To
characterize and compare the cognitively impaired (MCI
and mild AD dementia considered together, CI) group and
the control group, we applied descriptive statistics [48], the
Mann–Whitney test [49] for non-normally distributed data,
and Student’s t tests for independent samples. Comparison
of premorbid personality traits between clinical and control
subjects was performed using Welch’s t test [50]. To screen
for relations between premorbid personality traits and cere-
bral pathology we counted correlations for each NEO-PI-R,
Form R domain and each biomarker. Further, four-stage
multiple hierarchical regressions were conducted for the CI
and control groups combined to determine whether any of
the NEO personality traits contributed significantly to cog-
nitive performance, represented by the CDR SoB score. All
observations that were shown by Cook’s distance [51] to be
influential were eliminated from this analysis. We first in-
cluded age, gender, education level, APOEε4 expression
and cognitive status (Controls/CI) in our hierarchical re-
gression models to control for those variables that may
have an impact on the cognitive performance. In the sec-
ond step we examined the concentration of CSF bio-
markers. Then, each of the five main NEO-PI-R
personality domains was added separately in order to
assess the influence of personality traits on predicting
cognitive performance. Finally, we considered interac-
tions between each dimension of premorbid personal-
ity and concentration of CSF biomarkers. Different
regression models were compared and domain indices
were calculated.
Results
The descriptive statistics of the sample are presented in
Table 1. The CI and control groups differed significantly
in age, APOE ε4 status and CDR SoB score. There were
significantly more females than males in the control
group, although gender distribution in the clinical group
was equal. HAD depression and anxiety scores were
similar in both groups.
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Simple group comparisons
Welch’s t test performed on the informant-report data for
each of the five personality dimensions yielded a signifi-
cant difference in openness to experience scores in both
the control (M = 107; SD = 17.27) and CI (M= 94; SD =
17.22) groups (t(92.12) = 15.318, p < 0.001). Premorbid
personality traits in domains of neuroticism, extraversion,
agreeableness and conscientiousness did not differ be-
tween the two experimental groups (t(87.41) = 0.96, p =
0.33; t(107.61) = 1.58, p = 0.21; t(101.16) = 0.09, p = 0.76;
and t(90.06) = 1.19, p = 0.28 respectively). Moreover,
among the personality domains, only openness to experi-
ence was significantly correlated with MMSE score (r = –
0.243, p < 0.05) and CDR SoB score (r = 0.325, p < 0.01) in
the group with cognitive impairment.
Personality characteristics and CSF biomarkers
We applied Kendall’s tau [52] correlation analysis for
nonparametric data to investigate associations between
premorbid personality traits and concentrations of CSF
biomarkers (see Table 2). Because the biomarker values
were not normally distributed and contained outliers, we
eliminated those influential observations that had Cook’s
distance > 1 [51]. Correlation analysis revealed robust
negative associations between premorbid openness and
the levels of tau, ptau-181, tau/Aβ1–42 and ptau-181/
Aβ1–42. Likewise, premorbid extraversion correlated
negatively with tau, ptau-181, tau/Aβ1–42 and ptau-181/
Aβ1–42 biomarker concentrations.
Personality characteristics, CSF biomarkers and cognitive
performance
Hierarchical multiple regressions revealed that, after
controlling for age, gender, education level, APOEε4 ex-
pression and cognitive status, the low Aβ1–42 concentra-
tions (β = –0.281, p < 0.01), high tau/Aβ1–42 levels (β =
0.237, p < 0.01) and high ptau-181/Aβ1–42 levels (β =
0.422, p < 0.001) contributed significantly in predicting
the CDR SoB score. The concentrations of tau and ptau-
181 did not reach any significance in model loading.
In the third step, where ratings of each personality do-
main were considered, only openness to experience con-
tributed significantly in predicting the CDR SoB score
(in regression model with tau and Aβ1–42 , β = –0.19, p
< 0.05; with ptau and Aβ1–42 , β = –0.266, p < 0.01; with
tau/Aβ1–42 , β = –0.193, p < 0.05; with ptau/Aβ1–42 , β
= –0.252, p < 0.01). More precisely, after controlling for
age, gender, education level, APOEε4 expression, cogni-
tive status (Controls/CI) and biomarker concentrations,
low premorbid openness to experience was associated
with high CDR SoB score, and thus low cognitive
performance.
Furthermore, to investigate the modulation effect of
premorbid personality on the cognitive performance–
cerebral pathology relationship, we included the interac-
tions between each CSF biomarker concentration and
each personality domain in the last step of our model.
The interactions between premorbid neuroticism and
tau (β = –0.202, p < 0.05), premorbid neuroticism and
tau/Aβ1–42 (β = –0.357, p < 0.01), and premorbid neur-
oticism and ptau-181/Aβ1–42 (β = –0.359, p < 0.01) con-
centrations negatively correlated with CDR SoB score.
At high levels of neuroticism (i.e., 1 SD above mean)
higher concentrations of tau, tau/Aβ1–42 and ptau-181/
Aβ1–42 were related to low CDR SoB score. With low
neuroticism (1 SD below mean), higher levels of the
same biomarkers were associated with high CDR SoB
score, and thus poor cognitive functioning (see Fig. 1).
Interactions between agreeableness and tau/Aβ1–42
concentrations (β = 0.299, p < 0.01) and between agree-
ableness and ptau-181/Aβ1–42 concentrations (β = 0.206,
p < 0.01) contributed significantly to cognitive perform-
ance (Fig. 1). With high agreeableness, greater levels of
those two biomarkers predicted a high score of CDR
SoB, and thus poorer cognitive functioning; while with
low agreeableness, higher biomarker concentrations pre-
dicted a lower CDR SoB score, and thus better cognitive
functioning.
Finally, premorbid conscientiousness and Aβ1–42 (β
= –0.182, p < 0.05) and conscientiousness and ptau-181/
Aβ1–42 (β = –0.233, p < 0.05) interactions were shown to
be significant in predicting CDR SoB. At high conscien-
tiousness, lower CDR SoB score was predicted by higher
ptau-181/Aβ1–42 levels and lower Aβ1–42 levels; while at
low conscientiousness, greater ptau-181/Aβ1–42 levels
and lower Aβ1–42 levels predicted a higher CDR SoB
Table 2 Kendall’s correlations between premorbid personality domains and biomarkers
Neuroticism Extraversion Openness Agreeableness Conscientiousness
Aβ1–42 0.08 0.03 0.07 –0.02 0.04
tau 0.03 –0.17** –0.25*** –0.05 –0.06
ptau-181 0.01 –0.15** –0.25*** 0.00 –0.07
tau/Aβ1–42 0.00 –0.17** –0.24*** –0.04 –0.01
ptau-181/Aβ1–42 –0.03 –0.16* –0.25*** –0.01 –0.01
*p < 0.05, **p < 0.01, ***p < 0.001
Aβ amyloid beta, ptau phosphorylated tau
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score, and thus worse cognitive functioning. Figure 1
graphically shows the relationship between neuroticism,
agreeableness and conscientiousness and ptau-181/Aβ1–
42 as well as CDR SoB score as examples of premorbid
personality and biomarkers’ interaction effect on cogni-
tive performance.
Discussion
We have found that interactions between levels of pre-
morbid neuroticism, conscientiousness and agreeable-
ness and CSF biomarkers of AD pathology predict
cognitive performance in healthy older participants and
in subjects with MCI and mild AD dementia. Further-
more, lower premorbid openness independently pre-
dicted lower cognitive functioning after controlling for
biomarker concentrations. To our knowledge, our study
is the first to investigate the impact of premorbid per-
sonality on the relationship between cognitive function-
ing and CSF biomarkers of AD pathology.
There were associations between specific premorbid
personality traits and tau, ptau-181, tau/Aβ1–42 and
ptau-181/Aβ1–42 ratios, but we did not find any associ-
ation with the Aβ1–42 level. While tau/Aβ1–42 and ptau-
181/Aβ1–42 ratios may be considered markers of con-
comitant cerebral amyloid pathology and tau-related
neurodegeneration, their associations with personality
traits seem to be largely due to associations with the tau
and ptau-181 levels. One possible explanation for these
findings is that, in the clinical stages of AD, pathological
changes of CSF Aβ1–42 may have reached the maximum
level and remain relatively stable, while changes in tau
and ptau-181 concentrations are still ongoing and more
closely associated with cognitive performance [8].
Alternatively, premorbid personality characteristics may
contribute to cognitive reserve rather than directly to
the development of cerebral amyloid pathology. In this
way, premorbid personality would modify the magnitude
and dynamics of cognitive impairment related to neuro-
degeneration and tau pathology.
Furthermore, we observed that the effect of CSF bio-
markers on cognitive performance change depending on
the level of specific premorbid personality traits. More
precisely, at low levels of neuroticism, higher concentra-
tions of tau and higher tau/Aβ1–42 and ptau-181/Aβ1–42
ratios predicted poorer cognitive performance. At low
premorbid conscientiousness, higher Aβ1–42 and lower
ptau-181/Aβ1–42 ratios predicted worse cognitive func-
tioning, suggesting a protective effect of conscientious-
ness. These findings are partly in line with a clinical and
autopsy study [20], reporting premorbid conscientious-
ness to be significantly higher in dementia patients with
cerebral pathology compared with non-demented indi-
viduals confirmed at autopsy to have had cerebral AD
pathology. High neuroticism, however, acted as a vulner-
ability factor for AD [20]. In our study, higher levels of
neuroticism predicted worse cognitive functioning only
when the CSF tau levels and the tau/Aβ1–42 and ptau-
181/Aβ1–42 ratios are relatively low (i.e. suggesting the
absence of an AD biomarker profile). This might suggest
that there is a “cutoff point” related to cerebral path-
ology after which the interaction effect on cognitive per-
formance reverses. Finally, premorbid agreeableness
moderated the biomarker–cognitive performance rela-
tionship so that the high tau/Aβ1–42 and ptau-181/Aβ1–
42 concentrations predicted worse cognitive functioning
when agreeableness was high. Different results might be
Fig. 1 Significant premorbid personality and biomarker interaction effect on cognitive functioning. Dispersion diagram plot depicting the fit of a model
with predicted cognitive performance score (ordinate axis) and an interaction between biomarker concentrations (abscissa axis) and premorbid personality.
Lines, predicted centred values of premorbid personality traits. Left: with low neuroticism (N), greater ptau-181/Aβ1–42 concentrations predict lower CDR SoB
scores, and thus better cognitive functioning. With relatively small ptau-181/Aβ1–42 value, the interaction effect is inversed. Middle: interaction between high
agreeableness (A) level and high ptau-181/Aβ1–42 value predicts higher CDR SoB score, and thus lower cognitive functioning. Effect is inversed with
relatively small ptau-181/Aβ1–42 concentrations. Right: at low conscientiousness (C) level, greater ptau-181/Aβ1–42 concentrations predict poorer cognitive
performance (high CDR SoB score). With high C, smaller ptau-181/Aβ1–42 ratios predict better cognitive functioning (low CDR SoB score). CDR SoB Res
residuals of clinical dementia rating Sum of Boxes score, Aβ amyloid beta, ptau phosphorylated tau
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due to different study designs applied. Moreover, our
sample was comprised of controls and patients with
MCI or mild AD dementia unlike in the clinical-autopsy
study, where non-demented subjects were compared
with participants with dementia. Noteworthily, premor-
bid neuroticism, conscientiousness and agreeableness
considered independently did not predict cognitive func-
tioning and the observed interaction effects on cognition
were weak. This finding may be due to the fact that par-
ticipants with cognitive impairment were at different
stages of cognitive impairment and the age of clinical
onset was not considered. Overall, the effects found in
our sample need confirmation in further studies.
Our study also reveals a substantial premorbid personal-
ity role in distinguishing between the CI and control groups
because the two groups differed significantly in the domain
of openness. This finding may seem less expected because
clinical AD symptoms, such as troublesome behaviour [53]
and anxiety [54], and dementia risk [17, 18, 20, 55, 56] have
been described as mainly related to high neuroticism and
low conscientiousness. Only a few studies estimate the
openness to experience—a trait which refers to cognitive
curiosity and activity, imagination, sensitivity to culture and
arts, and behavioural flexibility [57]—to play an important
role in predicting dementia or AD. Duberstein et al. [58]
found that AD dementia risk was greater among subjects
who had not only higher neuroticism and lower
conscientiousness, but also lower openness to experience.
Furthermore, a longitudinal study comparing personality
traits in normal ageing and MCI showed that MCI subjects
had lower premorbid openness compared with healthy
controls [59].
Moreover, our results revealed that premorbid openness
predicts cognitive performance beyond the subject’s cogni-
tive status, demographic variables, APOEε4 status and
CSF biomarker level. In our study, openness was the only
personality domain from the FFM which contributed in-
dependently to cognitive performance. This finding is in
line with results from some previous studies. For instance,
Terry et al. [60] showed that openness, and not neuroti-
cism, was associated with better memory performance in
older adults with questionable dementia, even after con-
trolling for socio-demographic variables and cognitive
functioning [60]. However, no premorbid personality as-
sessment was performed and possible personality changes
related to dementia were not considered in this study. Fur-
thermore, Chapman et al. [61] revealed that in older sub-
jects not only higher extraversion and neuroticism but
also lower openness predicted worse average cognitive
function over 7 years. Persons who are more open dispose
a greater intellectual curiosity and have lifelong patterns
of cognitive activity, which probably facilitates processing
of new information, helps maintain cognitive functions
[62] and leads to better cognitive reserve [63]. Sharp et al.
[64] explain the implication of openness in sustained cog-
nitive functioning in terms of preserved differentiation
theory. This view suggests that people who were more
mentally active throughout their lives show superior pres-
ervation of their baseline cognitive activity while, accord-
ing to the differential preservation hypothesis, greater
mental activity not only enhances the level of cognitive
performance but also slows the trajectory of age-related
cognitive decline [65]. In a longitudinal study, subjects
with higher levels of openness in the second half of
their life span had higher performance across all cog-
nitive tests and scored less for cognitive decline, even
after controlling for education and activities of daily
living, but did not alter the trajectories of cognitive
performance over age, supporting the preserved dif-
ferentiation theory [64]. Along with these previous
findings, our results strongly suggest an implication
of premorbid openness in predicting cognitive func-
tioning in older persons. Conforming with our results,
higher premorbid openness to experience might be
one of the patterns of a resilient personality profile
which boost subjects’ cognitive reserve and may act
as a protecting factor against cognitive decline.
Inheritance of the APOEε4 allele is considered a major
genetic risk factor for non-familial AD [66–68]. As for
genotype–personality phenotype interactions, neuroti-
cism and extraversion were recently found to act as
moderators on the associations between the APOEε4
status and the two outcomes; that is, worse cognitive
function and incidence of AD dementia over a span of
6.5 years [28]. More precisely, the carriers of APOEε4
with high scores on neuroticism and extraversion had
poorer cognitive functioning and higher incidence of AD
compared with APOEε4 carriers with lower neuroticism
and extraversion scores. Biomarkers of cerebral path-
ology were not included in this study, however. In our
study, APOEε4 status differed across clinical and control
groups, but was not a significant predictor for cognitive
functioning.
The main strengths of our study are the use of vali-
dated instruments, the comprehensive personality and
clinical assessment, and the inclusion of factors with
established effects on the relationship between cerebral
pathology and clinical manifestations. Neuroticism, con-
scientiousness and extraversion—the domains widely de-
scribed in the literature to differ between cognitively
impaired subjects and healthy controls—did not predict
cognitive performance alone. The absence of associa-
tions may be due to a small sample size and thus having
a reduced statistical power compared with results ob-
tained from larger cohorts. Furthermore, the assessment
of personality characteristics was made by the subjects’
proxies and might have been biased by their relationship
with the participants. It should be noted that there is a
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good agreement between self-report and informant-
report ratings [69], but informant ratings tend to dis-
criminate more sensitively healthy control and demented
groups compared with self ratings [55]. In addition,
evaluating a subject’s premorbid personality retro-
spectively may be less precise than prospective per-
sonality evaluation due to potential memory bias, and
may be influenced by the impact of the cognitive de-
cline on the personal relationship between caregiver
and patient. The preclinical stage of AD is character-
ized by developing AD pathology in the absence of
symptoms. During the transition phase to clinical AD,
there is a gradual decline in cognition that can be
paralleled by subtle changes in non-cognitive clinical
features. The continuous progression from the pre-
clinical to the prodromal stage makes it impossible to
define a precise onset of the clinical state [70]. There
is very little evidence on the timeline of personality
change in relation to the onset of cognitive impair-
ment, especially considering biomarkers of AD path-
ology. While several studies have shown that
subjective cognitive complaints predict cognitive de-
cline and are associated with AD pathology, it is not
clear how early personality changes start. A recent
study found that subjects with MCI and high cerebral
Aβ burden expressed more burdensome coping strat-
egies, dismissive attitudes and dependency compara-
tive with healthy controls. In the same study,
cognitively normal participants with high Aβ burden
had more subjective cognitive complains than cogni-
tively normal participants with low/normal Aβ bur-
den, but did not express different coping strategies,
dismissive attitudes and dependency [71]. In this con-
text, we consider it unlikely that substantial pro-
dromal personality changes occur more than 5 years
before the onset of cognitive decline. However, we
cannot exclude the possibility that subtle personality
changes occur even earlier.
Conclusions
The interaction between premorbid neuroticism, con-
scientiousness and agreeableness and cerebral path-
ology as measured by CSF biomarkers predicts
cognitive functioning. Subjects with MCI and mild
dementia have lower premorbid openness compared
with healthy controls. Premorbid openness predicts
cognitive impairment independently of cerebral AD
pathology. Further studies with larger samples are
needed in order to confirm these findings and their
potential implications for prevention of cognitive de-
cline, and to better understand the nature of premor-
bid personality in relation to brain pathology and
cognitive performance.
Appendix 1
Table 3 Description of NEO-PI-R personality domains and facets scales
Neuroticism: identifies individuals who are prone to psychological distress
N1. Anxiety: level of free floating anxiety
N2. Angry Hostility: tendency to experience anger and related states
such as frustration and bitterness
N3. Depression: tendency to experience feelings of guilt, sadness,
despondency and loneliness
N4. Self-Consciousness: shyness or social anxiety
N5. Impulsiveness: tendency to act on cravings and urges rather than
reining them in and delaying gratification
N6. Vulnerability: general susceptibility to stress
Extraversion: quantity and intensity of energy directed outwards into the
social world
E1. Warmth: interest in and friendliness towards others
E2. Gregariousness: preference for the company of others
E3. Assertiveness: social ascendancy and forcefulness of expression
E4. Activity: pace of living
E5. Excitement Seeking: need for environmental stimulation
E6. Positive Emotions: tendency to experience positive emotions
Openness to Experience: the active seeking and appreciation of
experiences for their own sake
O1. Fantasy: receptivity to the inner world of imagination
O2. Aesthetics: appreciation of art and beauty
O3. Feelings: openness to inner feelings and emotions
O4. Actions: openness to new experiences on a practical level
O5. Ideas: intellectual curiosity
O6. Values: readiness to re-examine own values and those of authority
figures
Agreeableness: the kinds of interactions an individual prefers from
compassion to tough mindedness
A1. Trust: belief in the sincerity and good intentions of others
A2. Straightforwardness: frankness in expression
A3. Altruism: active concern for the welfare of others
A4. Compliance: response to interpersonal conflict
A5. Modesty: tendency to play down own achievements and be humble.
A6. Tender-Mindedness: attitude of sympathy for others.
Conscientiousness: degree of organization, persistence, control and
motivation in goal directed behavior
C1. Competence: belief in own self efficacy
C2. Order: personal organization
C3. Dutifulness: emphasis placed on importance of fulfilling moral obligations
C4. Achievement Striving: need for personal achievement and sense of direction
C5.Self-Discipline: capacity to begin tasks and follow through to
completion despite boredom or distractions.
C6. Deliberation: tendency to think things through before acting or speaking.
Exerted and adapted from P.T. Costa, R.R. McCrae. Hogrefe Ltd. The Test
People, Oxford. http://www.unifr.ch/ztd/HTS/inftest/WEBInformationssystem/
en/4en001/d590668ef5a34f17908121d3edf2d1dc/hb.htm
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